# UroGen Pharma Ltd. (URGN) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $34.40, market value $1.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). UroGen Pharma Ltd. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 8.9×**. Each dollar of revenue is priced at 8.9×.
- **Free-cash-flow yield: -9.5%** (5-yr avg -27.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 90.8%**. UroGen Pharma Ltd. keeps 90.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -35.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -139.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: 145.5%**. A 145.5% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 56.0%**. Return on all capital, debt included, is 56.0%: comfortably above what that capital costs.
- **Return on assets: -48.7%**. Each dollar of assets produces -48.7% of profit.

## Growth
- **Revenue growth (1 yr): 21.4%** (3-yr 19.5%/yr, 5-yr 56.2%/yr). Revenue grew 21.4% over the last year, against 56.2% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -7.8%**. Earnings per share fell 7.8%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: net cash**. UroGen Pharma Ltd. holds more cash than debt.
- **Current ratio: 4.01** (quick 4.01). Current assets cover the next year's liabilities 4.01 times.
- **Altman Z-score: 1.89**. A Z-score of 1.89 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. UroGen Pharma Ltd. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover UroGen Pharma Ltd.; the consensus is strong_buy, with an average price target of $60.00 (+74% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 67.9%** (YTD 46.7%, 3-mo -11.0%). The shares are up 67.9% over twelve months including dividends.
- **From 52-week high: -32.3%** (108.5% above the low). Trading 32% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 38**. An RSI of 38 is neutral.
- **Beta (1 yr): 1.25** (volatility 63%). Beta of 1.25 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=URGN · Page: https://foliofundamentals.com/stocks/urgn

Not investment advice.